COLORADO SPRINGS, CO — (Marketwired) — 05/04/16 — Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the
development of cannabis-based medicines, is pleased to publicly applaud the Drug Enforcement Agency (DEA) for their latest decision
to green light clinical trials on the effectiveness of smoked marijuana as a treatment option for post-traumatic stress disorder,
proposed Harborside resolution, and the re-scheduling for mass access to expanded treatments. These recent moves by the DEA seem to
be signaling the signs of changing times, the right Industry at the right time.
Cannabis Science believes this is it and the Company is very well positioned to move into mass expansion mode as new projects
and current drug development initiatives get underway and move forward with exponential growth and sharply increased value.
Fortune Story on MAPS PTSD Study approved by the DEA:
The DEA green-lit a clinical trial of smoked marijuana for the treatment